Human leukocyte interferon for the treatment of herpes zoster in patients with cancer.

T. C. Merigan, K. H. Rand, Richard B Pollard, P. S. Abdallah, G. W. Jordan, R. P. Fried

Research output: Contribution to journalArticle

219 Citations (Scopus)

Abstract

We tested the effect of human leukocyte interferon on early localized herpes zoster infections in three placebo-controlled, randomized double-blind trials involving 90 patients with cancer. There were no significant differences in pretreatment severity of infection or nature of underlying disease in the groups. Higher dosages of more purified interferon in the second and third trials produced a significant (P less than or equal to 0.01) decrease in cutaneous dissemination. No dissemination occurred in those receiving the highest dosage (5.1 x 10(5) U per kilogram per day) (P less than or equal to 0.025). The number of days of new-vesicle formation in the primary dermatome decreased (mean, 2.3 days, P less than or equal to 0.05) in this group. Treated patients had a trend toward less acute pain, and significantly (P less than or equal to 0.05) diminished severity of post-herpetic neuralgia, at the two highest dosage levels. Visceral complications were six times less frequent in interferon recipients. High-dosage interferon appeared effective in limiting cutaneous dissemination, visceral complications and progression within the primary dermatome.

Original languageEnglish (US)
Pages (from-to)981-987
Number of pages7
JournalNew England Journal of Medicine
Volume298
Issue number18
StatePublished - May 4 1978
Externally publishedYes

Fingerprint

Herpes Zoster
Interferon-alpha
Interferons
Neoplasms
Skin
Acute Pain
Neuralgia
Infection
Therapeutics
Placebos

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Merigan, T. C., Rand, K. H., Pollard, R. B., Abdallah, P. S., Jordan, G. W., & Fried, R. P. (1978). Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. New England Journal of Medicine, 298(18), 981-987.

Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. / Merigan, T. C.; Rand, K. H.; Pollard, Richard B; Abdallah, P. S.; Jordan, G. W.; Fried, R. P.

In: New England Journal of Medicine, Vol. 298, No. 18, 04.05.1978, p. 981-987.

Research output: Contribution to journalArticle

Merigan, TC, Rand, KH, Pollard, RB, Abdallah, PS, Jordan, GW & Fried, RP 1978, 'Human leukocyte interferon for the treatment of herpes zoster in patients with cancer.', New England Journal of Medicine, vol. 298, no. 18, pp. 981-987.
Merigan, T. C. ; Rand, K. H. ; Pollard, Richard B ; Abdallah, P. S. ; Jordan, G. W. ; Fried, R. P. / Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. In: New England Journal of Medicine. 1978 ; Vol. 298, No. 18. pp. 981-987.
@article{98e3a97245d747d8b726ce05c3ce4d83,
title = "Human leukocyte interferon for the treatment of herpes zoster in patients with cancer.",
abstract = "We tested the effect of human leukocyte interferon on early localized herpes zoster infections in three placebo-controlled, randomized double-blind trials involving 90 patients with cancer. There were no significant differences in pretreatment severity of infection or nature of underlying disease in the groups. Higher dosages of more purified interferon in the second and third trials produced a significant (P less than or equal to 0.01) decrease in cutaneous dissemination. No dissemination occurred in those receiving the highest dosage (5.1 x 10(5) U per kilogram per day) (P less than or equal to 0.025). The number of days of new-vesicle formation in the primary dermatome decreased (mean, 2.3 days, P less than or equal to 0.05) in this group. Treated patients had a trend toward less acute pain, and significantly (P less than or equal to 0.05) diminished severity of post-herpetic neuralgia, at the two highest dosage levels. Visceral complications were six times less frequent in interferon recipients. High-dosage interferon appeared effective in limiting cutaneous dissemination, visceral complications and progression within the primary dermatome.",
author = "Merigan, {T. C.} and Rand, {K. H.} and Pollard, {Richard B} and Abdallah, {P. S.} and Jordan, {G. W.} and Fried, {R. P.}",
year = "1978",
month = "5",
day = "4",
language = "English (US)",
volume = "298",
pages = "981--987",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "18",

}

TY - JOUR

T1 - Human leukocyte interferon for the treatment of herpes zoster in patients with cancer.

AU - Merigan, T. C.

AU - Rand, K. H.

AU - Pollard, Richard B

AU - Abdallah, P. S.

AU - Jordan, G. W.

AU - Fried, R. P.

PY - 1978/5/4

Y1 - 1978/5/4

N2 - We tested the effect of human leukocyte interferon on early localized herpes zoster infections in three placebo-controlled, randomized double-blind trials involving 90 patients with cancer. There were no significant differences in pretreatment severity of infection or nature of underlying disease in the groups. Higher dosages of more purified interferon in the second and third trials produced a significant (P less than or equal to 0.01) decrease in cutaneous dissemination. No dissemination occurred in those receiving the highest dosage (5.1 x 10(5) U per kilogram per day) (P less than or equal to 0.025). The number of days of new-vesicle formation in the primary dermatome decreased (mean, 2.3 days, P less than or equal to 0.05) in this group. Treated patients had a trend toward less acute pain, and significantly (P less than or equal to 0.05) diminished severity of post-herpetic neuralgia, at the two highest dosage levels. Visceral complications were six times less frequent in interferon recipients. High-dosage interferon appeared effective in limiting cutaneous dissemination, visceral complications and progression within the primary dermatome.

AB - We tested the effect of human leukocyte interferon on early localized herpes zoster infections in three placebo-controlled, randomized double-blind trials involving 90 patients with cancer. There were no significant differences in pretreatment severity of infection or nature of underlying disease in the groups. Higher dosages of more purified interferon in the second and third trials produced a significant (P less than or equal to 0.01) decrease in cutaneous dissemination. No dissemination occurred in those receiving the highest dosage (5.1 x 10(5) U per kilogram per day) (P less than or equal to 0.025). The number of days of new-vesicle formation in the primary dermatome decreased (mean, 2.3 days, P less than or equal to 0.05) in this group. Treated patients had a trend toward less acute pain, and significantly (P less than or equal to 0.05) diminished severity of post-herpetic neuralgia, at the two highest dosage levels. Visceral complications were six times less frequent in interferon recipients. High-dosage interferon appeared effective in limiting cutaneous dissemination, visceral complications and progression within the primary dermatome.

UR - http://www.scopus.com/inward/record.url?scp=0018260359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018260359&partnerID=8YFLogxK

M3 - Article

C2 - 347294

AN - SCOPUS:0018260359

VL - 298

SP - 981

EP - 987

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 18

ER -